Inhibitory Activities of GDX-365 on HMGB1-mediated Septic Responses

• Published in: Biotechnology and bioprocess engineering Vol. 28; no. 4; pp. 623 - 631
• Main Authors: Baek, Dong-Hyuk, Kim, Go Oun, Choi, Hui-Ji, Yun, Mi-Young, Park, Dong Ho, Song, Gyu Yong, Bae, Jong-Sup
• Format: Journal Article
• Language: English
• Published: Seoul The Korean Society for Biotechnology and Bioengineering 01.08.2023; Springer Nature B.V; 한국생물공학회
• Subjects: antiseptics; Biotechnology; Cecum; Chemistry; Chemistry and Materials Science; Endothelial cells; Ginsenosides; HMGB1 protein; Industrial and Production Engineering; Lipopolysaccharides; mice; Mortality; nucleoproteins; Panax; Permeability; Research Paper; Sepsis; Survival; survival rate; therapeutics; Umbilical vein; 생물공학; GDX-365; HMGB1; sepsis; permeability
• ISSN: 1226-8372; 1976-3816
• DOI: 10.1007/s12257-023-0043-2

GDX-365, is the main fraction of black ginseng comprising protopanaxatriol-type rare ginsenosides (ginsenosides Rg3, Rk1, and Rg5). High mobility group box 1 (HMGB1) is known as a late mediator of sepsis. There are no reported research on the antiseptic properties of GDX-365. The suppression of HMGB1 release and restoration of vascular barrier integrity have emerged as promising therapeutic approaches for sepsis management. In this study, we looked at how GDX-365 affected the survival rate and HMGB1-mediated septic responses in a mouse sepsis model. The mice were given GDX-365 following the HMGB1 challenge. Using sepsis mouse model by cecal ligation and puncture (CLP) and human umbilical vein endothelial cells (HUVECs), measurements of permeability, and septic animal mortality, the antiseptic activity of GDX-365 was evaluated under septic conditions. We discovered that GDX-365 greatly decreased the release of HMGB1 from CLP-induced release of HMGB1 in mice and Lipopolysaccharide-activated HUVECs. Inhibiting hyper-permeability in the animals and restoring HMGB1-mediated vascular disruption were other effects of GDX-365. Additionally, GDX-365 therapy decreased in vivo sepsis-related mortality. Our findings imply that GDX-365 is effective in the treatment of sepsis since it lowers HMGB1 release and septic mortality in vivo .